Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Moodys
Mallinckrodt
Dow
McKesson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,668,002

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 5,668,002
Title: DNA and polypeptide for tumor-associated antigen CO-029
Abstract:The human tumor-associated antigen CO-029 is a monoclonal antibody-defined, 27-34 kDa cell surface glycoprotein. A full-length cDNA clone for CO-029 is described. When transiently expressed in COS cells, the cDNA clone directs the synthesis of an antigen reactive with monoclonal antibody CO-029 in mixed hemadsorption and immunoblot assays. Sequence analysis reveals that CO-029 belongs to a family of cell surface antigens which includes the melanoma-associated antigen ME491, the leukocyte cell surface antigen CD37, and the Sm23 antigen of the parasitic helminth Schistosoma mansoni.
Inventor(s): Linnenbach; Alban J. (Philadelphia, PA), Koprowski; Hilary (Wynnewood, PA), Szala; Stanislaw (Philadelphia, PA)
Assignee: The Wistar Institute (Philadelphia, PA)
Application Number:07/575,567
Patent Claims:1. An intron-free DNA molecule which encodes a tumor-associated antigen, said antigen immunoreactive with monoclonal antibody CO-029.

2. The intron-free DNA molecule of claim 1 wherein the tumor associated antigen has a protein molecular weight of 26,044.

3. The intron-free DNA molecule of claim 1 wherein the amino acid sequence of said antigen is shown in FIG. 3.

4. The intron-free DNA molecule of claim 1 wherein the nucleic acid sequence is shown in FIG. 3.

5. The intron-free DNA molecule of claim i which is covalently linked to a vector which can replicate in E. coli.

6. The intron-free DNA molecule of claim 1 which causes expression of a protein in COS cells immunoreactive with monoclonal antibody CO-029.

7. An intron-free DNA molecule comprising a nucleic acid sequence shown in FIG. 3.

8. An intron-free DNA molecule which hybridizes under stringent conditions to DNA having the sequence shown in FIG. 3.

9. An intron-free DNA molecule which codes for a polypeptide consisting essentially of an extracellular domain of the CO-029 antigen.

10. A polypeptide consisting essentially of an extracellular domain of the CO-029 antigen.

11. The polypeptide of claim 10 wherein the domain comprises amino acids 34 to 57 of CO-029.

12. The polypeptide of claim 10 wherein the domain comprises amino acids 110 to 205 of CO-029.

13. The polypeptide of claim 10 which is covalently linked to an amino acid sequence which causes said polypeptide to be secreted from cells.

14. A preparation of CO-029 antigen which is entirely free of other human proteins.

15. The preparation of claim 14 wherein the antigen is made in non-human cells which have been transformed with a DNA molecule encoding said antigen.

16. Non-human cells transformed with a DNA molecule encoding CO-029 antigen.

17. Cells transformed with the DNA molecule of claim 1.

18. Cells transformed with the DNA molecule of claim 7.

19. Cells transformed with the DNA molecule of claim 8.

20. Cells transformed with the DNA molecule of claim 9.

Details for Patent 5,668,002

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial The Wistar Institute (Philadelphia, PA) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial The Wistar Institute (Philadelphia, PA) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial The Wistar Institute (Philadelphia, PA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Moodys
Dow
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.